Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Russia’s Sputnik V COVID-19 Vaccine Starts EU Rolling Review

‘A Major Step’ Towards Approval, Say Backers

Executive Summary

The Russian backers of the vaccine’s development say that if it receives a marketing authorization in the EU, distribution could begin in June this year.

You may also be interested in...



Will Serum Institute Join Strides, Gland On The Sputnik V Flight?

While speculation mounts about Serum Institute being next in line for an RDIF partnership, Gland Pharma and Strides unit Stelis sign up to make COVID-19 vaccine Sputnik V. Part of the 550 million dose output tied up from India so far could be consumed domestically, but exports are a possibility as demand from European countries is set to jump.

Russians Attack 'Negative' EMA Comments On National Sputnik V Authorizations

Politics are never far from the surface where coronavirus vaccines are concerned, as demonstrated by recent comments by the Sputnik V developers. 

Slovakia Becomes Second EU Country To OK Use Of Russian Vaccine

While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS143890

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel